Eric W. Thomas

Array ( [id] => 11767911 [patent_doc_number] => 09376486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-28 [patent_title] => 'Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/993983 [patent_app_country] => US [patent_app_date] => 2011-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 25 [patent_no_of_words] => 17525 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13993983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8536842 [patent_doc_number] => RE043823 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2012-11-20 [patent_title] => 'Human monoclonal antibody against coreceptors for human immunodeficiency virus' [patent_app_type] => reissue [patent_app_number] => 13/300340 [patent_app_country] => US [patent_app_date] => 2011-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 23 [patent_no_of_words] => 26292 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13300340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147841 [patent_doc_number] => 20130302364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'HIGHLY IMMUNOGENIC HIV P24 SEQUENCES' [patent_app_type] => utility [patent_app_number] => 13/884634 [patent_app_country] => US [patent_app_date] => 2011-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15396 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435029 [patent_doc_number] => 20140112936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'METHODS OF NEUTRALIZING VIRAL INFECTION' [patent_app_type] => utility [patent_app_number] => 13/884823 [patent_app_country] => US [patent_app_date] => 2011-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 20020 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10629803 [patent_doc_number] => 09347951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region' [patent_app_type] => utility [patent_app_number] => 13/882041 [patent_app_country] => US [patent_app_date] => 2011-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 14911 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13882041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10168271 [patent_doc_number] => 09198964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-01 [patent_title] => 'Recombinant subunit dengue virus vaccine' [patent_app_type] => utility [patent_app_number] => 13/881423 [patent_app_country] => US [patent_app_date] => 2011-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 16647 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13881423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7776315 [patent_doc_number] => 20120039894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'IDENTIFICATION OF THERAPEUTIC AGENTS FOR HIV INFECTION' [patent_app_type] => utility [patent_app_number] => 13/280070 [patent_app_country] => US [patent_app_date] => 2011-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 15297 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20120039894.pdf [firstpage_image] =>[orig_patent_app_number] => 13280070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8172398 [patent_doc_number] => 20120107910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-03 [patent_title] => 'RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/279250 [patent_app_country] => US [patent_app_date] => 2011-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5718 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0107/20120107910.pdf [firstpage_image] =>[orig_patent_app_number] => 13279250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8301041 [patent_doc_number] => 20120183597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'Method of inducing neutralizing antibodies to human immunodeficiency virus' [patent_app_type] => utility [patent_app_number] => 13/200865 [patent_app_country] => US [patent_app_date] => 2011-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 7655 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13200865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989721 [patent_doc_number] => 20130217002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'HIV-1 IGG3 RESPONSE IN ACUTE HIV-1' [patent_app_type] => utility [patent_app_number] => 13/877281 [patent_app_country] => US [patent_app_date] => 2011-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8732 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13877281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11357377 [patent_doc_number] => 09534020 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide' [patent_app_type] => utility [patent_app_number] => 13/876918 [patent_app_country] => US [patent_app_date] => 2011-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13798 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9227117 [patent_doc_number] => 08632782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-21 [patent_title] => 'Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region' [patent_app_type] => utility [patent_app_number] => 13/240849 [patent_app_country] => US [patent_app_date] => 2011-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 53296 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13240849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7669108 [patent_doc_number] => 20110318377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'Methylated TAT Polypeptides and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 13/230540 [patent_app_country] => US [patent_app_date] => 2011-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25073 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13230540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8232648 [patent_doc_number] => 08198088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-06-12 [patent_title] => 'Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)' [patent_app_type] => utility [patent_app_number] => 13/221952 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19213 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/198/08198088.pdf [firstpage_image] =>[orig_patent_app_number] => 13221952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8532945 [patent_doc_number] => 08309098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-13 [patent_title] => 'Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)' [patent_app_type] => utility [patent_app_number] => 13/222020 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19213 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13222020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7732480 [patent_doc_number] => 20120015423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-19 [patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA' [patent_app_type] => utility [patent_app_number] => 13/221108 [patent_app_country] => US [patent_app_date] => 2011-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 19123 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20120015423.pdf [firstpage_image] =>[orig_patent_app_number] => 13221108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13635279 [patent_doc_number] => 09844589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-19 [patent_title] => Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses [patent_app_type] => utility [patent_app_number] => 13/137517 [patent_app_country] => US [patent_app_date] => 2011-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 178 [patent_figures_cnt] => 301 [patent_no_of_words] => 19199 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13137517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7656824 [patent_doc_number] => 20110306093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-15 [patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA' [patent_app_type] => utility [patent_app_number] => 13/209539 [patent_app_country] => US [patent_app_date] => 2011-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19129 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20110306093.pdf [firstpage_image] =>[orig_patent_app_number] => 13209539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8883606 [patent_doc_number] => 20130156791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS' [patent_app_type] => utility [patent_app_number] => 13/814954 [patent_app_country] => US [patent_app_date] => 2011-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 18545 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13814954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7817491 [patent_doc_number] => 20120064111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-15 [patent_title] => 'ATTENUATED VACCINES FOR NON-SEGMENTED NEGATIVE SENSE RNA VIRUSES' [patent_app_type] => utility [patent_app_number] => 13/183232 [patent_app_country] => US [patent_app_date] => 2011-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14386 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20120064111.pdf [firstpage_image] =>[orig_patent_app_number] => 13183232 [rel_patent_id] =>[rel_patent_doc_number] =>)